Amylyx Pharmaceuticals (AMLX) Accumulated Expenses (2021 - 2026)

Amylyx Pharmaceuticals has reported Accumulated Expenses for 6 years, with the latest figure at $14.6 million in Q2 2026.

• On a quarterly basis, Accumulated Expenses fell 16.35% year-over-year to $14.6 million in Q2 2026; TTM through Jun 2026 was $14.6 million, a 16.35% decrease from a year earlier, with the FY2025 full-year figure at $17.9 million, down 25.22% from the prior year.
• Accumulated Expenses was $14.6 million for Q2 2026 at Amylyx Pharmaceuticals, up from $11.3 million in the prior quarter.
• The five-year high for Accumulated Expenses was $67.9 million in Q1 2024, with the low at $11.3 million in Q1 2026.
• Average Accumulated Expenses over 5 years is $31.3 million, with a median of $23.8 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses surged 194.16% in 2022, then plunged 82.22% in 2025.
• Over 5 years, Accumulated Expenses stood at $38.3 million in 2022, then surged by 50.67% to $57.7 million in 2023, then slumped by 58.51% to $23.9 million in 2024, then retreated by 25.22% to $17.9 million in 2025, then retreated by 18.43% to $14.6 million in 2026.
• The last three Accumulated Expenses figures came in at $14.6 million (Q2 2026), $11.3 million (Q1 2026), and $17.9 million (Q4 2025), per Business Quant data.